Baixar PDF
Artigo anterior
Voltar à página
Artigo seguinte
If you have problems to see the content please click here
Outros usuários também visualizaram estes artigos
ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY
A. Maiolino; P. Moreau; M. Dimopoulos; J. Mikhael; K. Yong; M. Capra; T. Facon; R. Hajek; I. Spicka; M. Risse; G. Asset; S. Macé; T. Martin;
Hematol Transfus Cell Ther. 2020;42 Supl 2:262-3
POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF OPTIMMISM BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS
M. Dimopoulos; K. Weisel; P. Moreau; L.D.A. Jr; D. White; J.S. Miguel; P. Sonneveld; M. Engelhardt; M. Jenner; A. Corso; J. Dürig; M. Pavic; M. Salomo; E. Casal; R. Jiang; T. Nguyen; T. Peluso; P. Richardson;
Hematol Transfus Cell Ther. 2020;42 Supl 2:272-3
BRAZILIAN REAL-WORLD MULTIPLE MYELOMA (MM) ELECTRONIC PLATFORM REGISTER PROJECT
E.Q. Crusoé; G. Ribeiro; K.R. Zanella; L.M. Perobelli; M.A.F. Aranha; M.E.Z. Capra; R.J.P. Magalhaes; J.F. Maciel; A. Maiolino; V.T. Hungria;
Hematol Transfus Cell Ther. 2020;42 Supl 2:253